Permira-backed Neuraxpharm takes two portfolios from Sanofi

• Neuraxpharm said it will broaden its global footprint and business with the deal
• Neuraxpharm, headquartered in Barcelona, is a European specialty pharmaceutical company
• London-headquartered Permira manages over €60bn of assets 

Neuraxpharm, backed by Permira, has completed the acquisition of two established product portfolios for central nervous system (CNS) disorders, pain, and vascular diseases from Sanofi.

Sanofi, based in Paris, France, is a global healthcare company.

Both portfolios include 17 molecules representing 38 brands that are marketed globally in over 50 countries for the benefit of patients across a large spectrum of diseases, the release said.

This will further cement Neuraxpharm’s position in Europe and broaden its global footprint and business.

“These newly acquired products not only strengthen our presence as a leading European specialty pharmaceutical company focused on CNS, but also lay the ground for further expansion of our international presence,” said Jörg-Thomas Dierks, chief executive officer of Neuraxpharm.

Neuraxpharm, headquartered in Sant Joan Despí, Barcelona, is a European specialty pharmaceutical company focused on the treatment of CNS disorders with presence in over 20 countries and over 1000 employees.

London-headquartered Permira has total assets under management of over €60 billion and makes long-term majority and minority investments across two core asset classes, private equity, and credit.